A Phase III, Randomized, Double Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD For the Treatment of BHeAg-Negative, Chronic Hepatitis B

Project: Research

Project Details

Project Description

SERP Reference Number: HREC/13/SHA/50
Monash Health HREC Ref: 13303A
Effective start/end date12/11/2011/11/25


  • Hepatitis B
  • treatment efficacy
  • treatment safety